Special Issue

The Control of Gut Microbiota: Antibiotics Alternatives and Fecal Microbiota Transplantation

Message from the Guest Editor

The gut microbiota plays a fundamental role in the health of living organisms due to its involvement in digestive metabolism, the immune system, brain function, etc. This implies that altering the gut microbiota, for example, through the use of antibiotics, leads to dysbiosis, which can trigger diseases or contribute to worsening pathophysiological conditions.

Antibiotics are the standard treatment of choice to combat bacterial infections, but they kill both harmful and beneficial bacteria, which can lead to a loss of microbial diversity and an imbalance between bacterial communities and those of other microorganisms present in the gastrointestinal tract (e.g., fungi, archaea, protists, algae, viruses).

There are several potential approaches to control and restore a healthy gut microbiota, including the use of probiotics, prebiotics, postbiotics, and fecal transplantation of microorganisms.
The aim of this Special Issue is to update and compile all the scientific knowledge that currently exists on alternatives to antibiotic treatments and the control of gut microbiota.

Guest Editor

Prof. Dr. Beatriz Vázquez Belda

Department of Analytical Chemistry, Nutrition and Bromatology, Faculty of Veterinary Science, University of Santiago de Compostela, 27002 Lugo, Spain

Deadline for manuscript submissions

closed (30 June 2024)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/163549

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI